# US 2024/0197964 A1 · Gel material for ophthalmic treatment use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197964 A1
- Document ID: US20240197964A1
- Status: Published application
- Kind: A1
- Application number: 18/595,720
- Filed: 2024-03-05
- Published: 2024-06-20
- Earliest claimed: 2016-01-06
- Assignees: The University of Tokyo; University of Tsukuba
- Applicants: The University of Tokyo; University of Tsukuba
- Inventors: Takamasa SAKAI; Yuichi TEI; Fumiki OKAMOTO; Sujin HOSHI
- Web page: https://patentgrep.com/patent/US20240197964A1

## CPC

- A61L 27/52: Hydrogels or hydrocolloids
- A61K 9/0051: {Ocular inserts or implants}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61L 27/14: Macromolecular materials
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61P 27/02: Ophthalmic agents
- C08G 65/329: with organic compounds
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS

## Abstract

Provided is a gel material for ophthalmic treatment useful as a synthetic vitreous body which is a novel intraocular tamponade material having a low swelling pressure, an appropriate elastic force, and no toxicity to ocular tissues, specifically, to retinas, and which is capable of stably maintaining a long-term stable tamponade effect. A gel material for ophthalmic treatment including a hydrogel in which a gel precursor cluster crosslinks to form a three-dimensional network. The gel precursor cluster has a structure with crosslinked monomer units or crosslinked polymer units present at concentrations less than a critical gelation concentration, and the gel precursor cluster has a relationship of G′<G″ where G′ represents a storage elastic modulus and G″ represents a loss elastic modulus. The hydrogel has a polymer content of 50 g/L or less, a storage elastic modulus G′ of 1 to 10,000 Pa at a frequency of 1 Hz, and a fractal dimension of 1.5 to 2.5.

## Claims

### Claim 1

A method of treating an ophthalmic disease in a subject, the method comprising:
administering into an eye of the subject a solution comprising gel precursor clusters, wherein after administration the gel precursor clusters form a hydrogel having a three-dimensional network of crosslinked gel precursor clusters in the eye of the subject,
wherein the gel precursor clusters have a structure where polymer units are crosslinked at a concentration less than a critical gelation concentration, the gel precursor clusters are in a sol state and have a relationship of G′<G″ where G′ represents a storage elastic modulus and G″ represents a loss elastic modulus, and the gel precursor clusters have a diameter in the range of 10 to 1000 nm,
wherein the hydrogel has a polymer content of 50 g/L or less, a storage elastic modulus G′ of 1 to 10,000 Pa at a frequency of 1 Hz, and a fractal dimension of 1.5 to 2.5,
wherein the gel precursor clusters comprise (i) a first polymer unit having one or more nucleophilic functional groups in a side chain or at an end of the first polymer unit, and (ii) a second polymer unit having one or more electrophilic functional groups in a side chain or at an end of the second polymer unit, wherein the first and second polymer units have three- or four-branched polyethylene glycol skeleton,
wherein the nucleophilic functional group is selected from the group consisting of an amino group and —SH, and the electrophilic functional group is selected from the group consisting of N-hydroxy-succinimidyl (NHS) group and a maleimidyl group,
wherein the hydrogel comprises the gel precursor clusters that have a diameter in the range of 10 to 1000 nm, and
wherein the first polymer unit and the second polymer unit have a molecular weight in the range of 5×103 to 5×104 Da.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the hydrogel has a loss elastic modulus G″ of 1 to 100 Pa.

### Claim 3 (depends on 1)

The method according to claim 1, wherein, in an aqueous solution, the hydrogel has a swelling pressure of 0.1 to 5 kPa and a swelling degree in a range where the volume of the hydrogel in a temperature of 30 to 40° C. changes from 90 to 500% of the volume at the time of gel formation.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the nucleophilic functional group is —SH, and the electrophilic functional group is a maleimidyl group.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the gel precursor clusters include a first gel precursor cluster and a second gel precursor cluster,
wherein the first gel precursor cluster has a content of the first polymer unit higher than a content of the second polymer unit, and
the second gel precursor cluster has a content of the second polymer unit higher than a content of the first polymer unit.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the loss elastic modulus G″ of the gel precursor cluster is in the range of 0.005 to 5 Pa at a frequency of 1 Hz.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the gel precursor clusters have a fractal dimension of 1.5 to 2.5.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the administering comprises intraocularly injecting the solution.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the solution further comprises a crosslinking agent.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the solution is injected into a vitreous cavity of the subject.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the hydrogel is used as a vitreous injectant.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the hydrogel is used as a synthetic vitreous body.
